• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom misses on EPS in Q4

February 11, 2022 By Sean Whooley

Dexcom updated logoDexcom (NSDQ:DXCM) shares are down slightly, a day after fourth-quarter results that were mixed compared to the consensus forecast.

The San Diego-based continuous glucose monitoring technology developer yesterday evening posted losses of $19.4 million, or 20¢ per share, on sales of $698.2 million for the three months ended Dec. 31, 2021, for a bottom-line slide into the red from profits of $355.2 million this time last year despite sales growth of 22.7%.

Adjusted to exclude one-time items, earnings per share were 68¢, 17¢ behind Wall Street, where analysts were looking for sales of $695.6 million.

The company reiterated that it has submitted its next-generation G7 CGM to the FDA in search of 510(k) clearance. Dexcom expects clearance in the near future.

“2021 was another great year for Dexcom, producing record customer growth, an expanded product and software portfolio, and further success in our ongoing campaign to improve global access,” Dexcom Chair, President and CEO Kevin Sayer said in a news release. “With the upcoming launch of G7 and several exciting initiatives planned for 2022, we look forward to another great year ahead.”

Dexcom expects full-year 2022 revenues to range between $2.82 billion and $2.94 billion.

DXCM shares were down slightly at $440.70 per share in morning trading. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up slightly.

This story originally ran on Feb. 10, 2022. Updated Feb. 11 with the stock price. 

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), MassDevice Earnings Roundup, Patient Monitoring, Regulatory/Compliance, Wall Street Beat Tagged With: Dexcom

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS